Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH
Business Wire•19/11/2026•08:00 ET
0
Key Highlights
- ➤Sonic Incytes and Madrigal Pharmaceuticals announce a multi-year MASH assessment partnership
- ➤Velacur ONE provides point-of-care, non-invasive liver stiffness and fat assessment
- ➤Partnership initially targets gastroenterology, hepatology and endocrinology settings
- ➤Madrigal Pharmaceuticals has an approved therapy for MASH
Expert Statements
Barry Allen, President and CEO of Sonic Incytes
“MASH remains significantly underdiagnosed, and too many patients are missed or identified only after their disease has advanced”
Barry Allen, President and CEO of Sonic Incytes
“We look forward to working with Madrigal to help clinicians deliver non-invasive liver assessments to the patients who need them, where they need them. We believe Velacur’s demonstrated accuracy, including our proprietary Velacur Determined Fat Fraction (VDFF), can help more patients be assessed earlier.”
Barry Allen, President and CEO of Sonic Incytes
“Clinicians need practical tools that fit their existing workflows.”
Barry Allen, President and CEO of Sonic Incytes
“Madrigal has helped transform what is possible for people living with MASH. Together, we want to make objective liver assessment easy to access, so more patients can be identified and evaluated at the point of care.”
Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH
Partnership aims to help more clinicians assess and risk-stratify patients with or at risk for metabolic dysfunction-associated steatohepatitis (MASH), using point-of-care liver assessment.
Get started
Create a free account to read the full story.
